400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Cell Cycle / PLK / Onvansertib
CAS No.: 1034616-18-6
Synonyms: NMS-1286937;NMS-P937;PCM-075
NMS-1286937 is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor (IC50=2 nM) with potential antineoplastic activity and no inhibition on PLK2 and PLK3.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT01014429 | Advanced or Metastatic Solid T... more >>umors Collapse << | Phase 1 | Completed | - | United States, Arizona ... more >> Arizona TGen Clinical Research Services at Scottsdale Heathcare Scottsdale, Arizona, United States, 85258 Collapse << |
实验方案
技术信息
CAS号 | 1034616-18-6 | 储存条件 |
|
|||||||
分子式 | C24H27F3N8O3 | 运输 | 蓝冰 | |||||||
分子量 | 532.52 | 别名 | NMS-1286937;NMS-P937;PCM-075 | |||||||
溶解度 |
|
动物实验配方 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT01014429 | Advanced or Metastatic Solid T... more >>umors Collapse << | Phase 1 | Completed | - | United States, Arizona ... more >> Arizona TGen Clinical Research Services at Scottsdale Heathcare Scottsdale, Arizona, United States, 85258 Collapse << |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网